SUPPLEMENTARY TABLES AND LEGENDS

Supplementary Table 1

Oligonucleotide primers used for RT-qPCR.

Primers	Sequence	Product length (bp)
cyclin E	F-5' GTTATAAGGGAGACGGGGAG 3' R-5' TGCTCTGCTTCTTACCGCTC 3'	205
CDK2	F-5' CCCTTTCTTCCAGGATGTGA 3' R-5' TCACCCCTGTATTCCCAGAG 3'	208
c-ETS1	F-5' GGATGGGCAAATCTGGTCTA 3' R-5' CCAGAATGGAGAAGGGAACA 3'	115
GAPDH	F-5' CGACCACTTTGTCAAGCTCA 3' R-5' AGGGGTCTACATGGCAACTG 3'	228

Supplementary Table 2

Oligos used for EMSA

Primers	Sequence				
Concensus	F- 5' CGTCTGCAGGATCCCA <u>GGAA</u> GGTGAGCATAGCCTAC 3'				
Consensus	R- 5' gtaggctatgctcacc $\underline{\text{ttcc}}$ tgggatcctgcagacg 3'				
cyc E	F-5' ACTCAGGGCCC <u>GGAA</u> CTCGGCGTCTC 3'				
	R-5' GAGACGCCGAG <u>TTCC</u> GGGCCCTGAGT 3'				
cyc E-mut	F-5' ACTCAGGGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC				
Cyc E-mut	R-5' GAGACGCCG <u>CTCGAG</u> GGGCCCTGAGT 3'				
CDK2	F-5' AGGGAAACGCG <u>GGAA</u> GCAGGGGCGGG 3'				
CDK2	R-5' CCCGCCCTGC <u>TTCC</u> CGCGTTTCCCT 3'				
CDK2-mut	F-5' AGGGAAACGC <u>TC</u> GA <u>G</u> GCAGGGGCGGG 3'				
CDK2-mut	R-5' CCCGCCCTGC <u>C</u> TC <u>GA</u> GCGTTTCCCT 3'				

The mutated bases are bold faced and underlined. Here, CDK2 represents only proximal c-ETS1 element of *CDK2* promoter.

Supplementary Table 3

Oligonucleotide	primers	used	for	MNase-southern,	MNase	CHART-PCR,	ChIP	and	ChIP-
qPCR.									

Primers	Sequence	Product length (bp)			
cyclin E	F-5' GGTGACCTTGGGGATGTCC 3'	146			
	R-5' AGCCAAGGGGATGTGTGG 3'	140			
CDK2	F-5' GGCTCTGACGTTGACCAATAGAAAG 3'	124			
CDK2	R-5' GGCCAACTTGAAACAATGTTGCC 3'	124			
CDK2-D	F-5' AGACAGTGTCGGGGGTATGCTATG 3'	157			
CDK2-D	R-5' CACCAATCCTGGGGAAAATATG 3'	137			

CDK2 represents only proximal c-ETS-1 element of CDK2 promoter.

SUPPLEMENTARY FIGURE LEGENDS

<u>Supplementary Fig. 1</u>. Schematic representation of cyclin E and *CDK2* promoters along with site directed mutant of c-ETS1 element. Schematic representation of cyclin E (A) or *CDK2* (B) promoters with either wild type or mutant c-ETS1 elements. The +1 represents the transcriptional start site. CAT and Luciferase are the reporter constructs used for assessing the promoter activity of cyclin E and *CDK2* respectively. * indicates the site directed mutant bases of the c-ETS1 element.


Supplementary Fig. 2. Transfection efficiency showed in terms of EGFP expression. Huh7 cells were transfected with pEGFP-C1 construct along with other expression vectors indicated in each transfection. 48h post-transfected cells were visualized under fluorescent microscopy (Nikon eclipse TE 2000-S) for EGFP expression.

Supplementary Fig. 3. Dose dependent activation and competitive inhibition of cyclin E and *CDK2* promoters by c-ETS1 and its dominant negative construct respectively. Relative CAT and luciferase activity of pE-WT and pCDK2-WT reporter transfected in Huh7 cells with either increasing concentrations of c-ETS1 plasmid (50, 100, 200 and 400ug) (A and B) or with c-ETS1 and c-ETS1 DN constructs (C and D). Data shown in *A-D* are the means \pm SD of three independent experiments. * - indicate statistically significant difference at p < 0.05.


Supplementary Fig. 4. Inhibition and induction of c-ETS1 protein respectively with increasing concentration of EGF treatment or c-ETS1 siRNA transfection. Western blot showing the expression of c-ETS1 protein in Huh7 cells either transfected with indicated siRNA at different concentration (*A*) or treated with increasing amounts of EGF (1, 2.5, 5, 10 and 50 ng/ml) (*B*).

Supplementary Fig. 5. HBx mediated stimulation of G_1/S phase progression is dependent on induction of cyclin E and *CDK2* genes by c-ETS1. FACS analysis was performed after transfection of Huh7 cells with indicated combinations of expression constructs along with siRNA against c-ETS1 and the percent live cells in G_1 and S phases were measured.


Supplementary Fig. 1




Supplementary Fig. 2



Supplementary Fig. 3



Supplementary Fig. 4



Supplementary Fig. 5

